A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2021-06-22
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Adalimumab; Methotrexate

Criteria

Inclusion Criteria:

• Diagnosis of RA based on 2010 ACR/EULAR for RA for at least a 4 month duration.

• Moderately to severely active RA based on local standard of care.

Exclusion Criteria:

-Evidence of untreated or inadequately treated latent or active TB.